Chimerix, Inc. (NASDAQ:CMRX) Files An 8-K Financial Statements and ExhibitsItem 9.01
| Exhibit No. | Description |
| 99.1 | Contract modification No. 41, dated July 24, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended. |
| 99.2 | Contract modification No. 42, dated August 25, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended. |
| 99.3 | Contract modification No. 43, dated September 22, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended. |
| 99.4* | Contract modification No. 44, dated September 28, 2017, to the contract by and between Chimerix, Inc. and the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services dated February 16, 2011, as amended. |
| * | Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. |
CHIMERIX INC ExhibitEX-99.1 2 tv476818_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (if applicable) 0041 See Block 16C N/A. 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA02 ASPR-BARDA 200 Independence Ave.,…To view the full exhibit click here
About Chimerix, Inc. (NASDAQ:CMRX)
Chimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against over five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir is marketed under the brand name Viread. The Company has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus.
